Royalty reassures BioLineRx on BL-1020 programme
This article was originally published in Scrip
Executive Summary
The new owners of Cypress Bioscience have reassured licensing partner BioLineRx over their commitment to continued development of BL-1020 (CYP-1020), the latter's candidate drug for schizophrenia.